UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT)
Buy Rating Affirmed for Rocket Pharmaceuticals Amidst Promising Drug Approvals and Strong Financials
Needham: Reiterated Rocket Pharmaceuticals (RCKT.US) rating, adjusted from buy to buy rating, target price $53.00.
Rocket Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target
Rocket Pharmaceuticals (RCKT) Receives a Buy From William Blair
Optimistic Buy Rating for Rocket Pharmaceuticals Based on Strong Gene Therapy Pipeline and Expert Leadership
Needham: Reiterated Rocket Pharmaceuticals (RCKT.US) rating, adjusted from buy to buy rating, target price $53.00.
Rocket Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $53 Price Target
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Q32 Bio (QTTB) and Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Rocket Pharmaceuticals Amid Promising Pipeline and Upcoming Commercial Launch
Rocket Pharmaceuticals Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals (RCKT) Receives a Buy From Stifel Nicolaus
No Data